Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05289167
Other study ID # 21-00797
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date March 13, 2022
Est. completion date December 2026

Study information

Verified date February 2024
Source NYU Langone Health
Contact Emma Futamura
Phone 212-731-6217
Email emma.futamura@nyulangone.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I-II clinical trial. Adult subjects with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the criteria defined in our standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Subjects will receive a standard of care conditioning regimen. Subjects will receive investigational PTCy, investigational bortezomib and investigational abatacept as GvHD prophylaxis.


Description:

The study will have a phase I and phase II potions. The phase I portion will employ a 3+3 dose escalation design to define the maximum tolerated dose (MTD) of abatacept added to PTCy and bortezomib following HSCT. The phase II portion will consist of two single arm, open label, optimal 2-stage Simon design studies conducted in two separate strata for HLA matched and HLA mismatched donor transplants. Adult patients with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the standard criteria defined in our institutional standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Subjects will receive a standard of care conditioning regimen followed by peripheral blood hematopoietic stem cells. Subjects with unrelated donors will also receive rabbit anti-thymocyte globulin (rATG). Subjects will receive investigational PTCy, investigational bortezomib and investigational abatacept as GvHD prophylaxis. The phase II portion dose of abatacept will be the MTD as determined in the phase I portion of the study. In the phase II portions, subjects will be stratified based on whether they receive a matched sibling or matched unrelated (matched) donor transplant and ≥7 out of 8, allele level matched (mismatched) unrelated donor transplant.


Recruitment information / eligibility

Status Recruiting
Enrollment 74
Est. completion date December 2026
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Age =18 years - Karnofsky score =70% - No evidence of progressive bacterial, viral, or fungal infection - Creatinine clearance >50 mL/min/1.72m2 - ALT and AST <3 x the upper limit of normal - Total bilirubin <2 x the upper limit of normal (except for Gilbert's syndrome) - Alkaline phosphatase =250 IU/L - Left Ventricular Ejection Fraction (LVEF) >45% - Adjusted Carbon Monoxide Diffusing Capacity (DLCO) >50% - Negative HIV serology - Negative pregnancy test: Confirmation per negative serum ß-human chorionic gonadotropin (ß-hCG) - Willing to comply with all study procedures and be available for the duration of the study. Exclusion Criteria: - Pregnant or nursing females or women of reproductive capability who are unwilling to completely abstain from heterosexual sex or practice 2 effective methods of contraception from start of conditioning through 90 days after the last dose of study drug. A woman of reproductive capability is one who has not undergone a hysterectomy (removal of the womb), has not had both ovaries removed, or has not been post-menopausal (stopped menstrual periods) for more than 24 months in a row. - Male subjects who refuse to practice effective barrier contraception from the start of conditioning through a minimum of 90 days after the last dose of study drug, or completely abstain from heterosexual intercourse. This must be done even if they are surgically sterilized (i.e., post-vasectomy). - Inability to provide informed consent. - Patient had myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see Appendix D), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant. - Known allergies to any of the components of the investigational treatment regimen. - Serious medical or psychiatric illness likely to interfere with participation in this clinical study. - Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma, an in-situ malignancy, or low-risk prostate cancer after curative therapy. - Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial. - Prisoners - Pregnant women

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cyclophosphamide
50 mg/kg IV over 1 hour on Day +3 and +4
Abatacept
Dose level 0: 10 mg/kg IV over 30 minutes on day +5 Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14 Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28
Bortezomib
1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.

Locations

Country Name City State
United States NYU Langone Health New York New York

Sponsors (1)

Lead Sponsor Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase I:Incidence Dose limiting toxicity (DLT) Defined as grade 4 non-hematologic toxicity affecting the oral cavity, gastrointestinal tract, lung, heart, liver, kidney, bladder, or central nervous system. Day+1 to Day +120
Primary Phase II: Grades II-IV Acute GvHD The first day of grades II-IV acute GvHD will be recorded for that grade. This end point will be evaluated through day +120 post-transplant. Day+1 to Day +120
Secondary Chronic GvHD The diagnosis of chronic GvHD is based on clinical and pathological evaluation by the principal investigator in collaboration with the treating physician.The analysis will be based on the maximum grade of chronic GvHD Day +1 to Day +365
Secondary Primary graft failure Incidence of graft failure will be calculated from date of transplant to failure for all subjects who receive a transplant and any prophylactic treatment and from date of completion of prophylactic treatment for all participants that completed treatment Day +1 to Day +30
Secondary Poor graft function Incidence of poor graft function will be calculated, from date of transplant to failure for all subjects who receive a transplant and any prophylactic treatment and from date of completion of prophylactic treatment for all participants that completed treatment Day +1 to Day +30
Secondary Secondary graft failure Evaluated after engraftment is achieved will be calculated from date of engraftment for all subjects with engraftment Day +1
Secondary Treatment-related mortality (TRM) Analyzed based on participants that who received a transplant with any prophylactic treatment and for all subjects who received a transplant and completed prophylactic treatment. Day +1 to Day +730
Secondary Relapse rate (RR) Evaluated to day +730 and will be analyzed for all subjects who received a transplant and for all transplanted subjects that completed treatment Day +1 to Day +730
Secondary GvHD and relapse-free survival (GRFS) Evaluated to day +730 and considers as successes participants that are without reported GvHD III-IV acute GvHD, chronic GvHD requiring systemic therapy and have not experienced relapse or death after transplant Day +1 to Day +730
Secondary Overall survival (OS) Evaluated to day +730 and considers all participants who received a transplant and for all transplanted subjects who completed prophylactic treatment Day +1 to Day +730
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01428973 - Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens Phase 2
Not yet recruiting NCT00749164 - Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment Phase 1/Phase 2
Completed NCT00993343 - Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation Phase 3
Completed NCT00360685 - Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX N/A
Active, not recruiting NCT04503616 - Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention Phase 1/Phase 2
Terminated NCT02080195 - Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE) Phase 1/Phase 2
Completed NCT02193880 - Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) N/A
Completed NCT02942173 - CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT Phase 2/Phase 3
Completed NCT02145403 - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Phase 1/Phase 2
Recruiting NCT01941394 - Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation Phase 2
Completed NCT00141713 - The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease Phase 2
Recruiting NCT01991301 - Carfilzomib for the Prevention of Graft Versus Host Disease Phase 1
Completed NCT00408928 - Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease Phase 2
Completed NCT01633229 - Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications Phase 1
Completed NCT05856058 - To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability Phase 1
Completed NCT02342613 - Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation Phase 1
Recruiting NCT06423131 - Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT N/A
Completed NCT02144025 - Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT Phase 2
Completed NCT01369914 - The Natural History of Graft-Versus-Host Disease in the Eyes
Completed NCT00806728 - Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease Phase 1